m6A-centered Crosstalk Information

Mechanism of Crosstalk between m6A Modification and Epigenetic Regulation
Crosstalk ID
M6ACROT05417
 [1]
m6A modification PVT1 PVT1 ALKBH5 Demethylation : m6A sites Direct Enhancement Non-coding RNA PVT1 Regulated Target  lncRNA       miRNA   circRNA
m6A Modification:
m6A Regulator RNA demethylase ALKBH5 (ALKBH5) ERASER
 Regulator Info 
m6A Target Pvt1 oncogene (PVT1)
 Targert Gene 
Epigenetic Regulation that have Cross-talk with This m6A Modification:
Epigenetic Regulation Type Non-coding RNA (ncRNA)
Epigenetic Regulator Pvt1 oncogene (PVT1) LncRNA View Details
Crosstalk Relationship m6A  →  ncRNA Enhancement
Crosstalk Mechanism m6A regulators directly modulate the functionality of ncRNAs through specific targeting ncRNA
Crosstalk Summary ALKBH5 decreased the m6A modification of Pvt1 oncogene (PVT1), thus inhibiting the binding of reader protein YTHDF2 in PVT1. ALKBH5-mediated PVT1 upregulation promoted the osteosarcoma cell proliferation in vitro and tumor growth in vivo.
Responsed Disease Osteosarcoma ICD-11: 2B51
 Disease Info 
Cell Process Cell proliferation
Cell colony formation
In-vitro Model
 SaOS-LM7 Osteosarcoma Homo sapiens CVCL_0515
SaOS-2 Osteosarcoma Homo sapiens CVCL_0548
HOS Osteosarcoma Homo sapiens CVCL_0312
U2OS Osteosarcoma Homo sapiens CVCL_0042
MG-63 Osteosarcoma Homo sapiens CVCL_0426
143B Osteosarcoma Homo sapiens CVCL_2270
NHOst (Normal human osteoblast cells)
In-vivo Model Indicated stable 143B cells were subcutaneously injected into nude mice.
Full List of Potential Compound(s) Related to This m6A-centered Crosstalk
2B51: Osteosarcoma 12 Compound(s) Regulating the Disease Click to Show/Hide the Full List
 Compound Name Cisplatin Approved [2]
Synonyms
Abiplatin; Biocisplatinum; Briplatin; Cismaplat; Cisplatine; Cisplatino; Cisplatinum; Cisplatyl; Citoplationo; Lederplatin; Neoplatin; Plastin; Platamine; Platidiam; Platinoxan; Randa; Cis-DDP; Cis-Diamminedichloroplatinum; Peyrone's chloride; Peyrone's salt; Cis-Dichlorodiammineplatinum(II); Cis-[PtCl2(NH3)2]; Cis-diamminedichloridoplatinum(II); Trans-diamminedichloridoplatinum(II); (SP-4-1)-diamminedichloridoplatinum; (SP-4-1)-diamminedichloroplatinum; (SP-4-2)-diamminedichloridoplatinum; (SP-4-2)-diamminedichloroplatinum; Cisplatin (Chemotherapy)
    Click to Show/Hide
External Link
CID: 5702198
TTD: D0U5HU
 Compound Name Naxitamab Phase 2 [2]
External Link
TTD: D0HI5D
 Compound Name Tideglusib Phase 2 [3]
Synonyms
NP-031112; NP-12; NP031112; Tideglusib(NP-031112)
    Click to Show/Hide
External Link
CID: 11313622
TTD: D0UT7X
DrugBank: DB12129
 Compound Name Hu3F8 mAb Phase 2 [4]
External Link
TTD: D0R4UA
 Compound Name Saracatinib Phase 2 [5]
Synonyms
H8H; AZD-0530; Saracatinib, AZD-0530, AZD0530; N-(5-Chloro-1,3-benzodioxol-4-yl)-7-(2-(4-methylpiperazin-1-yl)ethoxy)-5-(tetrahydro-2H-pyran-4-yloxy)quinazolin-4-amine
    Click to Show/Hide
External Link
CID: 10302451
TTD: D0M0XB
DrugBank: DB11805
 Compound Name ALMB-0168 Phase 1/2 [6]
External Link
TTD: DXAI94
 Compound Name AU101 Phase 1/2 [7]
External Link
TTD: D0T9JW
 Compound Name [153Sm]CycloSam Phase 1 [8]
External Link
TTD: D8W1DJ
 Compound Name GD2 T cells Phase 1 [9]
External Link
TTD: D0QB7N
 Compound Name Anti-GD2-CAR engineered T cells Phase 1 [10]
External Link
TTD: D09DND
 Compound Name Robatumumab Discontinued in Phase 2 [11]
External Link
TTD: D0X9RN
 Compound Name DG-8 Investigative [12]
Synonyms
DH-9; PPAR gamma agonists (osteosarcoma/ADPKD); PPAR gamma agonists (osteosarcoma/ADPKD), Chinese Academy of Sciences
    Click to Show/Hide
External Link
TTD: D0L3VC
References
Ref 1 ALKBH5-mediated m(6)A demethylation of lncRNA PVT1 plays an oncogenic role in osteosarcoma. Cancer Cell Int. 2020 Jan 30;20:34. doi: 10.1186/s12935-020-1105-6. eCollection 2020.
Ref 2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
Ref 3 Evidence for irreversible inhibition of glycogen synthase kinase-3Beta by tideglusib. J Biol Chem. 2012 Jan 6;287(2):893-904. doi: 10.1074/jbc.M111.306472. Epub 2011 Nov 18.
Ref 4 ClinicalTrials.gov (NCT02502786) Humanized Monoclonal Antibody 3F8 (Hu3F8) With Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) in the Treatment of Recurrent Osteosarcoma.
Ref 5 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7731).
Ref 6 ClinicalTrials.gov (NCT04886765) A Phase I/II, Multi-center, Single-Arm, Open-Label Study to Evaluate the Safety and Efficacy of ALMB-0168 in Patients With Osteosarcoma. U.S.National Institutes of Health.
Ref 7 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
Ref 8 ClinicalTrials.gov (NCT03612466) A Dose Finding Study of CycloSam Combined With External Beam Radiotherapy. U.S. National Institutes of Health.
Ref 9 ClinicalTrials.gov (NCT01953900) iC9-GD2-CAR-VZV-CTLs/Refractory or Metastatic GD2-positive Sarcoma and Neuroblastoma
Ref 10 ClinicalTrials.gov (NCT02107963) A Phase I Trial of T Cells Expressing an Anti-GD2 Chimeric Antigen Receptor in Children and Young Adults With GD2+ Solid Tumors
Ref 11 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800027277)
Ref 12 The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.